NOGRA PHARMA LIMITED

NOGRA Pharma Limited is a Dublin‑based pharmaceutical and R&D management company specialising in the discovery and early‑stage development of new therapeutic agents for immune‑inflammatory‑mediated diseases. The firm takes projects from target validation through to Phase II proof‑of‑concept clinical studies, leveraging a portfolio of platforms that include oligonucleotides, aryl‑hydrocarbon‑receptor (AhR) modulators and selective progesterone receptor modulators (SPPARM).

Nogra Pharma’s business model centres on long‑term R&D collaborations. It partners with universities and research institutes to source innovative targets, and works with pharmaceutical and biotech companies to advance development and eventual commercialisation. Recent activities include an out‑licensing agreement with Torii Pharmaceutical for a new topical acne treatment in Japan and a series of publications on Smad7‑based approaches to intestinal inflammation and Crohn’s disease.

The company serves academic researchers seeking development expertise, pharma and biotech firms looking for partner pipelines, and ultimately patients who will benefit from novel treatments for immune‑mediated conditions. Nogra Pharma also offers detailed project presentations and confidential discussions to explore collaboration or out‑licensing opportunities.